Remicade carries a Boxed Warning for risk of serious infections and cancer.
Remicade有一个对严重感染和癌症风险的黑框警告。
Remicade belongs to a class of drugs called tumor necrosis factor (TNF) blockers.
Remicade属于被称为肿瘤坏死因子(TNF)阻断剂类药物。
After 26 weeks of treatment, patients getting the combination had a 57% chance of disease remission, compared to 44% of those getting Remicade alone and to 30% of those getting azathioprine alone.
经过26周的治疗,联合用药的病人中有57%获得缓解,与之相比,在单用英夫利昔单抗组中只有44%而单用硫唑嘌呤组中只有30%得到缓解。
After 26 weeks of treatment, patients getting the combination had a 57% chance of disease remission, compared to 44% of those getting Remicade alone and to 30% of those getting azathioprine alone.
经过26周的治疗,联合用药的病人中有57%获得缓解,与之相比,在单用英夫利昔单抗组中只有44%而单用硫唑嘌呤组中只有30%得到缓解。
应用推荐